Clinical trial
Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma
NCT00360945 · Children's Cancer and Leukaemia Group, Other · Unknown status
Key facts
| NCT number | NCT00360945 |
|---|---|
| Title | Cisplatin and Temozolomide in Treating Young Patients With Malignant Glioma |
| Official title | Phase II Study of the Combination of Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents at Diagnosis or in Relapse |
| Lead sponsor | Children's Cancer and Leukaemia Group, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug, Genetic, Other, Radiation |
| Interventions | cisplatin, temozolomide, fluorescence in situ hybridization, loss of heterozygosity analysis, immunohistochemistry staining method, laboratory biomarker analysis, radiation therapy |
| Enrollment | 87 |
| Start date | Apr 1, 2004 |
| First posted | Aug 7, 2006 |
| Last update posted | Sep 17, 2013 |
| Countries | France, Ireland, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: